Net Income Common - Central Pharmaceutical JSC No3 (VN:DP3)

Company	Net Income (Common)	CAGR 3Y	CAGR 5Y	CAGR 10Y
C	Central Pharmaceutical JSC No3 VN:DP3	Net Income (Common) ₫129.1B	CAGR 3-Years 4%	CAGR 5-Years 6%	CAGR 10-Years 31%
H	HaTay Pharmaceutical JSC VN:DHT	Net Income (Common) ₫72.9B	CAGR 3-Years 4%	CAGR 5-Years -10%	CAGR 10-Years 10%
I	Imexpharm Corp VN:IMP	Net Income (Common) ₫319.7B	CAGR 3-Years 16%	CAGR 5-Years 14%	CAGR 10-Years 14%
C	Cuu Long Pharmaceutical JSC VN:DCL	Net Income (Common) ₫53.6B	CAGR 3-Years -15%	CAGR 5-Years -9%	CAGR 10-Years 5%
D	Dhg Pharmaceutical Joint-Stock Co VN:DHG	Net Income (Common) ₫891.3B	CAGR 3-Years 0%	CAGR 5-Years 5%	CAGR 10-Years 7%
T	Traphaco JSC VN:TRA	Net Income (Common) ₫223.6B	CAGR 3-Years -4%	CAGR 5-Years 6%	CAGR 10-Years 4%

Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.

Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.

By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.

Close

The most important thing to me is figuring out how big a moat there is around the business. What I love, of course, is a big castle and a big moat with piranhas and crocodiles.

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

Close

By using Alpha Spread you are agreeing to our
Terms of Service and Privacy Policy.

Companies most frequently analyzed and tracked by Alpha Spread users.

	Johnson & Johnson NYSE:JNJ	206.54 USD 3.29%
	Berkshire Hathaway Inc NYSE:BRK.A	735 276 USD -0.14%
	Bank of America Corp NYSE:BAC	54.08 USD 1.01%
	Mastercard Inc NYSE:MA	538.86 USD 0.24%
	UnitedHealth Group Inc NYSE:UNH	328.37 USD 1.47%
	Exxon Mobil Corp NYSE:XOM	119.54 USD 1.09%

View Most Popular Stocks Full List

Every business has a fair value, its true price. Where market price tells you the price other people are willing to pay, fair value shows the value of a stock based on an analysis of the company’s actual financials (such as cash balance, revenue, operating margin, etc).

	Franklin Covey Co NYSE:FC	16.43 USD 1.67%
	Mohawk Industries Inc NYSE:MHK	111.7 USD 4.82%
	Ardmore Shipping Corp NYSE:ASC	11.41 USD -1.13%
	ASGN Inc NYSE:ASGN	46.48 USD 2.67%
	Skyworks Solutions Inc NASDAQ:SWKS	68.81 USD 0.39%
	Weatherford International PLC NASDAQ:WFRD	81.31 USD 1.51%

View Most Undervalued Stocks Full List

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term.

	Johnson & Johnson NYSE:JNJ	206.54 USD 3.29%
	Bank of America Corp NYSE:BAC	54.08 USD 1.01%
	Mastercard Inc NYSE:MA	538.86 USD 0.24%
	Salesforce Inc NYSE:CRM	264.2 USD 1.22%
	Abbvie Inc NYSE:ABBV	225.18 USD 0.98%
	Home Depot Inc NYSE:HD	351.13 USD 1.7%

View Wide Economic Moat Stocks Full List

Companies demonstrating exceptional profitability and efficient operations.

	Monolithic Power Systems Inc NASDAQ:MPWR	979.02 USD 1.67%
	Applovin Corp NASDAQ:APP	703.28 USD -2.94%
	NVIDIA Corp NASDAQ:NVDA	183.78 USD -0.64%
	Cal-Maine Foods Inc NASDAQ:CALM	85.96 USD -0.37%
	Pro Medicus Ltd ASX:PME	233.155 AUD -1.51%
	Lundin Gold Inc TSX:LUG	109.08 CAD 1.4%

View High Profitability Stocks Full List

Companies with the lowest probability of bankruptcy.

	Salesforce Inc NYSE:CRM	264.2 USD 1.22%
	Accenture PLC NYSE:ACN	272.22 USD 1%
	ServiceNow Inc NYSE:NOW	853.56 USD -0.16%
	Spotify Technology SA NYSE:SPOT	609.41 USD 3.35%
	TJX Companies Inc NYSE:TJX	155.67 USD 1.29%
	Micron Technology Inc NASDAQ:MU	263.71 USD 4.47%

View High Solvency Stocks Full List

By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.

Central Pharmaceutical JSC No3
VN:DP3

Central Pharmaceutical JSC No3
Net Income (Common)

Central Pharmaceutical JSC No3
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Central Pharmaceutical JSC No3
Glance View

See Also

What is Central Pharmaceutical JSC No3's Net Income (Common)?

Net Income (Common)
129.1B VND

What is Central Pharmaceutical JSC No3's Net Income (Common) growth rate?

Net Income (Common) CAGR 10Y
31%

Company

Help

Tools

Stocks

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication
US	Chevron Corp NYSE:CVX	Energy

52 Week Range	49 800 62 700
Price Target

Central Pharmaceutical JSC No3 VN:DP3

Central Pharmaceutical JSC No3 Net Income (Common)

Central Pharmaceutical JSC No3 Net Income (Common) Peer Comparison

Competitors Analysis Latest Figures & CAGR of Competitors

Central Pharmaceutical JSC No3 Glance View